Caroline Moore (academic): Difference between revisions

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
({{Scholia|author}})
(no need to display the parentheses)
 
Line 28: Line 28:
   
 
==External links==
 
==External links==
{{Scholia|author}}
+
{{Scholia|author|Caroline Moore}}
 
* {{Google Scholar id|0wG6b20AAAAJ}}
 
* {{Google Scholar id|0wG6b20AAAAJ}}
   

Latest revision as of 17:58, 20 May 2019

Caroline Moore
Born
Caroline M. Moore
Alma materSt George's, University of London
University College London
Scientific career
InstitutionsUniversity College London
University College London Hospital

Caroline M. Moore is a Professor of Urology at University College London. She works in the diagnosis and treatment of prostate cancer. She was the first woman to be made a Professor of Urology in the United Kingdom.

Early life and education[edit]

Moore was born in Chester, and moved to Wombourne at the age of five. She studied at St Edmunds Catholic College. She studied medicine at St George's, University of London, and graduated in 1997.[1] She completed her medical training in London, before starting her MD on photodynamic therapy in 2002.[2]

Research and career[edit]

Moore was awarded a research fellowship from the Royal College of Surgeons. She is based in the Department of Urology at University College London Hospital (UCLH) and the Division of Surgical & Interventional Sciences at University College London (UCL).[3] UCL/UCLH has a leading diagnostic research programme for prostate cancer, including urologists, radiologists, engineers and computer medical imaging specialists.[3][4] She has a variety of research interests, including the use of magnetic resonance imaging (MRI) and non-traditional follow-up methods.[5][6] Her research has been supported by the Movember Foundation.[7]

Moore has used MRI to identify prostate cancer and target biopsies.[2][8] Moore started using MRI to detect prostate cancer in men who would not need treatment, and found that if biopsies were performed before MRI scans the images were blurred.[9] In October 2012 she established a committee on Standards in Reporting in MRI-targeted biopsy (START).[10] The recommendations included reporting histologic results of standard cores using Gleason scores and maximum core cancer length, as well as reporting the recruitment criteria, radiologist experience and population biopsy status of a particular trial.[10] She has worked on a combination of multi-parametric MRI and cognitive fusion transperineal biopsy, which can reduce the time taken diagnose and treat diseases.[11] She has found that using MRI can reduce the need for biopsies by 28%.[12][13][14] Her MRI protocols have been rolled out across the United Kingdom.[9]

Moore has developed electronic psychometric patient-reported outcome measures to monitor men who have had radical prostatectomy.[3] Men who have this surgery can suffer from urinary leakage and difficulties with erections. The survey allows researchers to track their progress and share information with their surgical teams.[15] Moore has recently been among a group of researchers spread across six hospitals who have been investigating high-intensity focused ultrasound (HIFU) as a treatment for prostate cancer. Five years after treatment with HIFU the cancer survival rate is 100%, the same as for the more traditional methods of surgery and radiotherapy, but with fewer side-effects.[16]

She has been Head of Urology at University College London, within the Division of Surgical and Interventional Sciences since 2018. She was recently senior author on the Prostate Evaluation for Clinically Important Disease: Sampling Using Image Guidance or Not? (PRECISION) study comparing standard prostate biopsy and MRI-targeted biopsy.[17][18] The paper was awarded The BMJ "UK Research Paper" of the year.[6] In 2019 Moore was the first woman in the United Kingdom to be made a Professor of Urology.[1] She serves on the board of the European Association of Urology Research Foundation.[19]

She has served as a science consultant for the science comic Surgeon X.[20]

References[edit]

  1. ^ a b "Professor Caroline Moore Inaugural Lecture". Eventbrite. Retrieved 2019-03-30.
  2. ^ a b "Caroline Moore - Consultant Urological Surgeon London - LUA". www.lua.co.uk. Retrieved 2019-03-30.
  3. ^ a b c "Frontiers of Oncology | Caroline Moore". University College London. Retrieved 2019-03-30.
  4. ^ UCL (2018-10-19). "Caroline Moore". UCL School of Life and Medical Sciences. Retrieved 2019-05-11.
  5. ^ "Professor Caroline Moore". www.uclh.nhs.uk. Retrieved 2019-03-30.
  6. ^ a b "Winners 2019". The BMJ Awards. Retrieved 2019-05-11.
  7. ^ "Movember Global Outcomes Project | Macmillan Survivorship Research Group | University of Southampton". www.southampton.ac.uk. Retrieved 2019-03-30.
  8. ^ Caroline M. Moore; Nicola L.Robertson; Nasr Arsanious; Thomas Middleton; Arnauld Villers; Laurence Klotze; Samir S.Taneja; Mark Emberton (January 2013). "Image-Guided Prostate Biopsy Using Magnetic Resonance Imaging–Derived Targets: A Systematic Review". www.sciencedirect.com. 63 (1): 125–140. Retrieved 2019-03-30.CS1 maint: Multiple names: authors list (link) reproduced in Science Direct
  9. ^ a b Moore, Caroline Monitoring and treating prostate cancer on YouTube 10 July 2018
  10. ^ a b Moore, Caroline M.; Kasivisvanathan, Veeru; Eggener, Scott; Emberton, Mark; Fütterer, Jurgen J.; Gill, Inderbir S.; Grubb Iii, Robert L.; Hadaschik, Boris; Klotz, Laurence. "Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group". European Urology. 64 (4): 544–552. doi:10.1016/j.eururo.2013.03.030. ISSN 1873-7560. PMID 23537686.
  11. ^ Bass, Edward James; Freeman, Alex; Jameson, Charles; Punwani, Shonit; Moore, Caroline M; Arya, Manit; Emberton, Mark; Ahmed, Hashim Uddin (October 2018). "Prostate cancer diagnostic pathway: Is a one-stop cognitive MRI targeted biopsy service a realistic goal in everyday practice? A pilot cohort in a tertiary referral centre in the UK". BMJ Open. 8 (10): e024941. doi:10.1136/bmjopen-2018-024941. ISSN 2044-6055. PMC 6224764. PMID 30361408.
  12. ^ "MRI for prostate cancer diagnosis could change clinical practice | UCLH Biomedical Research Centre". www.uclhospitals.brc.nihr.ac.uk. Retrieved 2019-03-30.
  13. ^ Malewar, Amit (2018-07-05). "Prostate cancer ultrasound treatment as effective as surgery or radiotherapy". Tech Explorist. Retrieved 2019-03-30.
  14. ^ "Study finds prostate MRI scans both increase detection of cancer and reduce over-diagnosis". www.birmingham.ac.uk. 19 March 2018. Retrieved 2019-03-30.
  15. ^ Moore, Caroline M. "True NTH UK – Post Surgical Follow up". Health Research Authority. Retrieved 2019-03-30.
  16. ^ Wighton, Kate (4 July 2018). "Prostate cancer ultrasound treatment as effective as surgery or radiotherapy". Imperial News. Imperial College London. Retrieved 2019-03-30.
  17. ^ Kasivisvanathan, Veeru; Rannikko, Antti S.; Borghi, Marcelo; Panebianco, Valeria; Mynderse, Lance A.; Vaarala, Markku H.; Briganti, Alberto; Budäus, Lars; Hellawell, Giles (2018-05-10). "MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis". The New England Journal of Medicine. 378 (19): 1767–1777. doi:10.1056/NEJMoa1801993. ISSN 1533-4406. PMID 29552975.
  18. ^ "EAU 2018: Major Study Shows Prostate MRI Reveals More Cancers Which Need Treatment and Reduces Overdiagnosis Compared to Standard Biopsy". UroToday. 2018. Retrieved 2019-05-13.
  19. ^ Professionals, Sumedia-Online. "The EAU Research Foundation". Uroweb. Retrieved 2019-05-11.
  20. ^ "Our Team – SurgeonX". Retrieved 2019-03-30.

External links[edit]